A novel transgenic mouse model for immunological evaluation of carcinoembryonic antigen–based DNA minigene vaccines
J. Clin. Invest. He Zhou, et al. 113:1792 doi:10.1172/JCI21107 [Go to this article.]

Figure 7
DNA minigene vaccine pHI-691 exhibits HLA-A2–restricted antitumor effects in CEA-A2Kb double transgenic mice. Groups of mice (n = 7–10) were immunized three times at 2-week intervals with attenuated S. typhimurium harboring the vectors indicated. Mice were challenged 2 weeks after the last immunization subcutaneously with 5 ∞ 10S⁵ MC-38-CEA-A2Kb, MC-38, or MC-38-CEA cells. Mice were sacrificed 28 days later and tumor weights assessed. (A) MC-38-CEA-A2Kb tumor weight, the horizontal bar showed the average. (B) Average tumor weight of each group of mice (n = 8) challenged with different tumor cells. Top shows MC-38 tumor size; bottom shows average MC-38-CEA tumor weight. *P < 0.02 compared with pCMV group.